As their results imply, integrating proteomic and imaging data improved early detection of NAFLD and suggested that PON1 may serve as both a biomarker and therapeutic target in obesity-associated liver disease. Here, PON1 is linked to metabolic dysfunction-associated steatotic liver disease.